Our Correspondent
Hyderabad: Raising serious medical and public health concerns, the World Allergy Foundation (WAF) has urged Prime Minister Narendra Modi to reconsider the proposed blanket rollout of Human Papillomavirus (HPV) vaccination across India, cautioning that a one-size-fits-all approach may expose a significant section of the population to avoidable health risks.
At a press conference held in Hyderabad on Tuesday, WAF President Dr. Vyakarnam Nageshwar announced that a formal representation has already been submitted to the Prime Minister’s Office. The appeal, sent through a detailed two-page communiqué dated March 7, 2026, calls for a more nuanced, medically guided vaccination strategy rather than universal administration.
Marking the occasion, the Foundation also unveiled a striking public awareness slogan — “HPV Vaccination Not for All” — aimed at drawing attention to potential allergic risks associated with certain vaccine components.
Concerns Over Yeast-Based Vaccines
At the heart of the WAF’s appeal lies a scientific concern regarding HPV vaccines manufactured using Saccharomyces cerevisiae, commonly known as baker’s yeast. Dr. Nageshwar explained that while HPV vaccines are globally recognized for their role in preventing cervical cancer, their composition warrants caution in specific patient groups.
He pointed out that residual yeast proteins present in the final vaccine product could trigger allergic reactions in individuals with hypersensitivity to yeast. According to him, this risk is not merely theoretical but well-documented in international vaccine guidelines and product monographs for recombinant yeast-based vaccines.
“The contraindication is explicit — individuals with known yeast hypersensitivity should not be administered such vaccines without proper evaluation,” Dr. Nageshwar stated.
Alarming Findings from Local Study
Backing the Foundation’s concerns with clinical data, Dr. Nageshwar cited a retrospective analysis conducted at the Aswini Allergy Centre in Hyderabad. The study, which examined 300 patients, reportedly found that over 40 percent exhibited some degree of hypersensitivity to yeast.
Describing the figure as “remarkably high,” he warned that proceeding with mass vaccination campaigns without prior screening could lead to a surge in adverse reactions, particularly in school-based or community-wide immunization drives where individual medical histories are often not thoroughly assessed.
Range of Allergic Reactions
Elaborating on the risks, the WAF outlined a wide spectrum of possible allergic responses linked to yeast hypersensitivity. These reactions may occur immediately or within hours of exposure and can vary in severity.
Common manifestations include skin-related symptoms such as intense itching, hives (urticaria), red rashes, eczema flare-ups, and swelling of the face, lips, or tongue. Respiratory complications may involve sneezing, wheezing, nasal congestion, shortness of breath, chest tightness, and asthma-like attacks.
Gastrointestinal symptoms such as nausea, vomiting, abdominal cramps, diarrhea, and bloating have also been reported. In more severe cases, patients may experience systemic reactions, including rapid heartbeat, dizziness, a drop in blood pressure, difficulty in breathing or swallowing, and, in extreme situations, anaphylaxis — a life-threatening emergency requiring immediate medical intervention.
“These are not rare or isolated incidents. They are medically recognized responses that demand due diligence before administering vaccines at scale,” Dr. Nageshwar emphasized.
Call for Policy Recalibration
While clarifying that the Foundation is not opposed to vaccination per se, Dr. Nageshwar stressed the need for a calibrated and individualized approach that prioritizes patient safety.
“The objective is not to undermine immunization efforts but to strengthen them through scientific prudence. Public health policies must account for population-specific sensitivities,” he said.
Key Recommendations
The World Allergy Foundation has put forward a set of recommendations aimed at minimizing risks while ensuring that vaccination programs remain effective and safe.
Foremost among these is the introduction of mandatory pre-vaccination clinical screening. This would include a detailed medical history to identify individuals with known or suspected severe yeast hypersensitivity.
The Foundation has also called for the formulation of national guidelines for healthcare providers, clearly outlining screening protocols, contraindications, and referral pathways to allergy and immunology specialists when necessary.
In addition, it has emphasized the need to strengthen post-vaccination monitoring systems and ensure transparent reporting of adverse events. Such measures, it argues, would not only enhance patient safety but also build public trust in immunization programs.
Balancing Public Health and Individual Safety
India has been actively considering expanding HPV vaccination coverage as part of its broader strategy to combat cervical cancer, one of the leading causes of cancer-related deaths among women in the country. However, the WAF’s intervention highlights the complexities involved in implementing large-scale health interventions in a diverse population.
Medical experts note that while vaccines remain one of the most effective tools in disease prevention, their deployment must be accompanied by adequate safeguards, especially when specific risk factors are known.
As the Centre evaluates its HPV vaccination policy, the WAF’s appeal adds an important dimension to the ongoing discourse — the need to balance public health imperatives with individualized medical considerations.
Whether the government will revisit its approach in light of these concerns remains to be seen, but the debate has undoubtedly brought renewed focus on the importance of evidence-based policymaking in public health.
